BD Biosciences Announces Agreement with Dynomics to Collaborate on Novel Cancer Diagnostic Technology

31-Mar-2006

BD Biosciences, a segment of BD, announced a licensing and research agreement with Dynomics BV in the fields of leukemia and lymphoma. Under terms of the agreement, BD has an exclusive worldwide license to specific intellectual property related to the flow cytometry detection of fusion proteins. Financial terms were not disclosed.

Fusion proteins are unique proteins generated by a rearrangement of the chromosomes in a cell. Some disease states such as leukemia are characterized and sub-grouped by chromosomal rearrangements that generate well-recognized changes in cellular composition. Detection and identification of these proteins are important markers for diagnosing and monitoring leukemias. Dynomics focuses on the diagnosis and classification of leukemias and malignant lymphomas.

Other news from the department business & finance

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

See the theme worlds for related content

Topic World Cell Analysis

Cell analyse advanced method allows us to explore and understand cells in their many facets. From single cell analysis to flow cytometry and imaging technology, cell analysis provides us with valuable insights into the structure, function and interaction of cells. Whether in medicine, biological research or pharmacology, cell analysis is revolutionizing our understanding of disease, development and treatment options.

5+ products
5 whitepaper
5+ brochures
View topic world

Topic World Cell Analysis

Cell analyse advanced method allows us to explore and understand cells in their many facets. From single cell analysis to flow cytometry and imaging technology, cell analysis provides us with valuable insights into the structure, function and interaction of cells. Whether in medicine, biological research or pharmacology, cell analysis is revolutionizing our understanding of disease, development and treatment options.

5+ products
5 whitepaper
5+ brochures